# Filana Therapeutics, Inc.: overview FLNA · Nasdaq · CIK 1069530 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/flna.md) · [Financials](/companies/flna/financials.md) · [Filings](/companies/flna/filings.md) · [Insiders](/companies/flna/insiders.md) Latest reported revenue: [$35.2m](/filings/0001069530-16-000052.md) for Q4 FY2013, three months to 2013-12-31, from the 10-K filed Mar 3, 2016 (XBRL us-gaap:SalesRevenueNet, accession 0001069530-16-000052). ## Last eight quarters | Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.13](/filings/0001437749-25-026686.md) | [(0.58)](/filings/0001437749-25-034427.md) | not reported | [(0.48)](/filings/0001437749-25-015478.md) | [(0.92)](/filings/0001437749-25-026686.md) | [(0.22)](/filings/0001437749-25-034427.md) | not reported | not reported | | Free cash flow | $m | [(18.3) d](/filings/0001437749-25-026686.md) | [(18.3) d](/filings/0001437749-25-034427.md) | [(61.3) d](/filings/0001437749-26-007962.md) | [(11.3)](/filings/0001437749-26-015664.md) | [(4.9) d](/filings/0001437749-25-026686.md) | [(6.3) d](/filings/0001437749-25-034427.md) | [(10.2) d](/filings/0001437749-26-007962.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.82)](/filings/0001069530-22-000011.md) | [(1.90)](/filings/0001437749-25-005919.md) | [(2.32)](/filings/0001437749-26-007962.md) | [(1.46)](/filings/0001437749-26-007962.md) | [(1.88)](/filings/0001437749-26-007962.md) | | Free cash flow | $m | [(52.4)](/filings/0001437749-24-005894.md) | [(80.2)](/filings/0001437749-25-005919.md) | [(82.4)](/filings/0001437749-26-007962.md) | [(117)](/filings/0001437749-26-007962.md) | [(32.8)](/filings/0001437749-26-007962.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/flna/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.4m | 1,974,981 | | Added +44,038 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $2.0m | 1,711,358 | | Reduced −277,456 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.9m | 1,597,548 | | Reduced −414,995 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.7m | 1,453,561 | | Added +39,047 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $795.9k | 668,792 | | Added +627,468 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $732.7k | 615,510 | | Added +19,268 | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $577.2k | 485,025 | | Reduced −74,180 | | [GMT Capital Corp](/funds/1106191.md) | 2026-06-30 | $535.6k | 450,100 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $463.6k | 389,601 | | Added +62,842 | | [Squarepoint Ops LLC](/funds/1642575.md) | 2026-06-30 | $378.9k | 318,380 | | New +318,380 | ## Recent filings [All 853 filings](/companies/flna/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 12:17 ET | [8-K](/filings/0001437749-26-032971.md) | 8.01 Other events | 0001437749-26-032971 | | 2026-09-22 | 12:00 ET | [8-K](/filings/0001171843-26-006161.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-006161 | | 2026-09-18 | 20:16 ET | [8-K](/filings/0001437749-26-030751.md) | 3.01 Delisting notice | 0001437749-26-030751 | | 2026-07-29 | 12:28 ET | [10-Q](/filings/0001437749-26-024752.md) | Quarterly report, period 2026-06-30 | 0001437749-26-024752 | | 2026-07-29 | 12:15 ET | [8-K](/filings/0001171843-26-004982.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-004982 | | 2026-06-15 | 10:23 ET | [8-K](/filings/0001437749-26-020562.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-020562 | | 2026-05-07 | 21:16 ET | [10-Q](/filings/0001437749-26-015664.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015664 | | 2026-05-07 | 12:10 ET | [8-K](/filings/0001171843-26-003119.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003119 | | 2026-04-28 | 20:04 ET | [DEF 14A](/filings/0001437749-26-013654.md) | Proxy statement, period 2026-06-11 | 0001437749-26-013654 | | 2026-04-28 | 20:01 ET | [8-K](/filings/0001437749-26-013638.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-013638 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-007962.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1069530 - Tickers: FLNA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.